The STEAP4 pathway was pharmacologically targeted in BC cells, with an iron chelating drug (Deferiprone) with simultaneous blockage of the HER2 pathway with the tyrosine kinase inhibitor Lapatinib, which demonstrated an additive therapeutic potential involvement of STEAP4 in cancer. Here, ERBB2 is linked to breast cancer.